New drug AZD2389 targets scarred livers in tiny early trial

NCT ID NCT07069725

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 28, 2026 · Updated 5 times

Summary

This early study tests whether a single dose of the experimental drug AZD2389 can attach to a protein called FAP in the liver. Twelve adults with advanced liver scarring (fibrosis) will get a PET scan before and after taking the drug to see if it binds to its target. The goal is not to treat the disease yet, but to learn if the drug works as designed in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD2389
What this could lead to: If successful, this could show that AZD2389 reaches its target in the liver, supporting further development as a potential treatment for liver fibrosis.
What could go wrong: This is a very early, small study with only 12 participants. It only measures drug binding, not whether the drug improves liver health. Many early-stage drugs fail to show benefit in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver fibrotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATIC CIRRHOSIS LIVER FIBROSIS

Contacts and locations

Locations

Research Site

Stockholm, 17176, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.